| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| BRAWLEY OTIS W | Director | C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO | /s/ Charles Newton, as Attorney-in-Fact | 19 May 2025 | 0001213029 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | LYEL | Common Stock | 35,640 | 15 May 2025 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LYEL | Option (right to buy) | Award | $0 | +130,000 | $0.000000 | 130,000 | 15 May 2025 | Common Stock | 130,000 | $0.4017 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date. |